Cellromax Science Co Ltd

Cellromax Science Co Ltd maintains a strong liquidity position with a current ratio of 5.2, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score is high, supported by KRW 6.8 billion in cash and equivalents and a low debt-to-equity ratio of 0.01. Profitability metrics show a return on equity (ROE) of 6.32% and a return on assets (ROA) of 5.83%, both exceeding the industry median for health and wellness retailers. These figures suggest efficient use of equity and assets to generate returns. The company's revenue is concentrated in its core health food and cosmetics segments, with no disclosed geographic diversification. This concentration may expose the company to regional demand fluctuations, though the lack of international revenue breakdown limits further assessment. Outlook data indicates a projected revenue increase of 8.2% in the current fiscal year and 5.1% in the following year. This growth trajectory is supported by a history of stable revenue and operating income, with a 12.2% year-over-year revenue increase in the latest reported period. Risk assessment reveals low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is conservative, with minimal long-term debt and no dilution pressure from recent share issuance or shelf registration. Recent filings and transcripts do not disclose material events affecting the company's operations or financial position. The absence of significant regulatory or operational risks in the latest disclosures supports the low-risk assessment.